Want to join the conversation?
In 2Q16, $REGN reported positive data from three Phase III studies of dupilumab, a drug for eczema, an itchy skin condition. The company has submitted Biologics License Application for dupilumab in the U.S. $REGN expects FDA action for Sarilumab, a drug for treating rheumatoid arthritis, by October 30.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?